Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 9/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24936312 | 1.00 | EPHA2 (0.48) | EPHA2EPHB4ERBB2CHEK1KCNH2 | |
| SCHEMBL30190300 | 0.91 | EPHA2 (0.52) | EPHA2EPHB4ERBB2NR1H4P2RX3 | |
| SCHEMBL23084832 | 0.91 | EPHA2 (0.52) | EPHA2EPHB4ERBB2NR1H4P2RX3 | |
| SCHEMBL24936313 | 0.87 | ALOX5AP (0.45) | CHEK1KCNH2MEN1KMT2APDE4B | |
| SCHEMBL24936158 | 0.86 | CHEK1 (0.41) | CHEK1KCNH2MEN1KMT2APDE4B | |
| SCHEMBL24936295 | 0.83 | CHEK1 (0.66) | CHEK1KCNH2 | |
| SCHEMBL24936186 | 0.83 | CHEK1 (0.66) | CHEK1KCNH2 | |
| SCHEMBL24936208 | 0.79 | CHEK1 (0.43) | CHEK1KCNH2GPR119 | |
| SCHEMBL24935425 | 0.78 | CHEK1 (0.44) | CHEK1KCNH2GPR119 | |
| SCHEMBL24936288 | 0.77 | CHEK1 (0.42) | CHEK1KCNH2PDE4BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | EPHA2 3238/4885EPHB4 4591/4885ERBB2 922/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | EPHA2 3238/4885EPHB4 4591/4885ERBB2 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.